Tiered Overweight initiated at $350, overriding Underweight and Sell, with $315 hard stop and three-tranche accumulation framework
Overweight rating is the only rating that survives all binding lessons: 9/1 reflection forbids pre-committed Underweight at 38%+ off highs with intact quality prints (eliminates Trader's trim-and-wait and Research Manager's Underweight); 9/2 reflection forbids full conviction without MA reclaim but 9/4 reflection explicitly overrides MA-reclaim requirement for starter tranche at this drawdown; 9/3 reflection requires hard-dated forced re-decision (mid-November 2026 embedded); 9/4 reflection (most recent, most directly applicable) explicitly endorses tiered add at $328–356 with $315 stop — current price $350 is midpoint of that band. Hold rating explicitly disqualified as it produced −4.0% alpha in most recent ISRG decision (worst on record).
| Position | Action |
|---|---|
| Tranche 1 — Starter (25–33% of intended full position) | Entry at current spot $350 within $328–356 band; stop $315 hard structural |
| Tranche 2 — Confirmation Add (25–33%) | Trigger A: $328–356 retest with RSI <35 and bullish divergence OR volume climax >3M shares with intraday reversal; Trigger B: Daily close ≥$358 on volume >2.5M shares with RSI >45; stop trails to $322 |
| Tranche 3 — Trend Reclaim Add (33–40%) | Confirmed daily close above $379 (50 SMA) with flattening slope and volume >2.5M for 2 consecutive sessions; backup: MACD positive crossover sustained 5+ sessions with expanding histogram; stop trails to $348 |
| Position size cap | 1.5x benchmark maximum even on all tranches filled (per 8/31 Hold lesson; beta 1.465 warrants hawkish macro constraint) |
| Hedging overlay | 3–6 month $320–340 strike puts on residual position as tail-risk hedge |
| Avoid | Covered-call overlay (9/1 reflection flags this as wrong structure at this drawdown — caps recovery into $400–440) |
| Avoid | Adding on bounces into collapsing 50 SMA below $379 (Conservative Analyst correct that every bounce into falling 50 SMA in stagflationary tape is a seller gift) |
The 30%+ drawdown represents a classic capitulation and sentiment washout, not a fundamental deterioration — ISRG's accelerating fundamentals (FCF nearly doubled to $2.49B, margins expanding 830bps, 5 straight beats) combined with a 29x forward P/E and PEG of 0.76 make this a generational entry point in a category-killer with a two-decade moat.
| Indicator | Value | Signal |
|---|---|---|
| 10 EMA | $368.36 | bearish |
| 50 SMA | $379.92 | bearish |
| 200 SMA | $462.82 | bearish |
| RSI(14) | 35.11 | neutral |
| MACD Line | -5.08 | bearish |
| MACD Signal | -2.88 | bearish |
| MACD Histogram | -2.20 | bearish |
| Bollinger Upper Band | $408.29 | bearish |
| Bollinger Middle Band | $379.55 | bearish |
| Bollinger Lower Band | $350.81 | bearish |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Current spot $350 (within 9/4 reflection $328–356 entry band); no MA reclaim required per 9/4 override of 9/2 constraint
Then: 25–33% of intended full position; hard stop $315
Medtronic's $700M Hugo threat is a rounding error against ISRG's two-decade moat
↩ rebuts: “Medtronic's $700M Threat”
EV: Target $408 (upper Bollinger), $463 (200 SMA reclaim), then re-test of $600 prior high · concedes: Technical setup is genuinely ugly — bear correctly identifies Bollinger Band breakdown, MACD failure, bearish stacking; 40x trailing P/E is a lagging indicator reflecting the recent price collapse (though forward P/E is 29x); 8% recession odds for 2026 are not zero
ISRG's decline is not capitulation but the beginning of a longer structural downtrend driven by decelerating growth, competitive erosion, inventory buildup, and macro headwinds that will continue to compress the stock's premium valuation.
· concedes: The business is world-class; The moat is real today (though eroding); Every bounce is a gift to sellers until 200 SMA is reclaimed; Wait for 200 SMA reclaim before considering long thesis
→ vs conservative: Moving average trim logic is anchoring bias—200 SMA at $463 reflects COVID-era multiple expansion, not normalized valuation; ISRG has already completed 30%+ of required multiple compression
→ vs conservative: Backward-looking MA analysis has cost investors billions over decades; new normal for quality compounders in higher-for-longer regime is compressed multiples, not reversion to Fed-pump levels
→ vs neutral: HOLD is described as the most dangerous position—forces watching a 50% gain ($350 to $525) pass by while waiting for confirmed bottom; doing nothing with a 45%-off quality compounder is malpractice, not prudence
→ vs aggressive: The trader's SELL and 25-40% trim is capitulation-by-committee; too cautious given extraordinary opportunity at current levels
| ATR(14) |
| $11.93 |
| neutral |
Support: 340 · 328 · 347.52 | Resistance: 368.36 · 379.92 · 408.29 · 462.82
ISRG exhibits a strongly bearish technical setup with price ($350.16) below all major moving averages and below the lower Bollinger Band ($350.81) — a statistically rare event occurring in approximately 5% of sessions. The MACD family indicators show decisively negative momentum with a failed bullish crossover attempt in mid-August, and the histogram is expanding negatively at -2.20. While RSI at 35.11 is approaching oversold territory (the stock previously printed 28.99 on 7/23), it has not yet re-tested extreme oversold levels. The ATR compression to $11.93 from July peaks of $17.18 suggests volatility and selling pressure may be moderating, potentially setting up a tactical mean-reversion opportunity if RSI breaks below 30 alongside a bullish MACD histogram contraction and price reclaiming the lower Bollinger Band. Key resistance sits at $368 (10 EMA), $380 (50 SMA), and $408 (Bollinger upper band), while support zones are at $340 and $328.
Market Cap
$125.45B
P/E (TTM)
40.1x
Forward P/E
29.0x
PEG Ratio
1.6
P/B
6.82x
EPS (TTM)
$8.73
Forward EPS
$12.07
Beta
1.465
52-Week Range
$328.57 – $603.88
50-Day MA
$381.01
200-Day MA
$463.81
Total Revenue (FY2025)
$10.06B
Gross Profit (FY2025)
$6.64B
Operating Income (FY2025)
$2.95B
Net Income (FY2025)
$2.86B
Diluted EPS (FY2025)
$7.87
Gross Margin
~66.0%
Operating Margin
29.3%
Net Margin (TTM)
28.4%
R&D Spend
$1.31B
SG&A
$2.39B
Tax Rate
~13.1%
Total Assets (FY2025)
$20.46B
Total Equity (FY2025)
$17.82B
Total Liabilities (FY2025)
$2.52B
Long-Term Debt
$0
Cash & ST Investments
$5.93B
Current Ratio
4.96x
Working Capital
$7.77B
Debt-to-Equity
0.0x
ROE
17.4%
ROA
10.5%
PP&E (Net)
$5.34B
Inventory
$1.84B
Receivables
$1.63B
Goodwill & Intangibles
$381M
Operating Cash Flow (2025)
$3,031M
Capital Expenditures (2025)
-$540M
Free Cash Flow (2025)
$2,491M
Stock Buybacks (2025)
-$2,295M
Stock-Based Compensation
$788M
Depreciation & Amortization (2025)
$677M
End Cash Position (2025)
$3,407M
Q2 2026 Revenue
$2.89B
Q2 2026 Operating Income
$972M
Q2 2026 Net Income
$818M
Q2 2026 Diluted EPS
$2.29
FCF/Net Income
~87%
Strengths
Concerns
Intuitive Surgical is a mega-cap healthcare company (~$125.5B market cap) that dominates robotic-assisted minimally invasive surgery with its da Vinci platform. The company demonstrates exceptional fundamental quality: accelerating revenue growth (20.5% YoY to $10.06B in FY2025), high-quality earnings expansion (EPS CAGR of ~29.5% outpacing revenue CAGR of ~17.4%), expanding operating margins (from 25.3% to 29.3%), and a fortress balance sheet (zero debt, $5.93B cash, 4.96x current ratio). Cash conversion is strong with FCF of $2.49B (87% of net income), and management is aggressively returning capital via buybacks ($2.3B in FY2025). Despite a premium trailing P/E of 40.1x, the forward P/E of 29.0x against ~38% expected EPS growth and a PEG of 1.6 offer reasonable value for a category leader with durable recurring revenue. The recent pullback (trading below 200-day MA) may present an attractive entry point for patient long-term investors, though near-term valuation premium and macro sensitivity warrant a measured approach.
Macro: Fed-hold priced for all of 2026 (93% no cuts probability per Polymarket, $8.16M volume); US recession by end of 2026 only 8% (Polymarket, $1.74M volume) — no recession consensus supportive of healthcare equipment capex normalization. Iran conflict is active and escalating with $65M Polymarket volume on US invasion by 2027; oil surging on 9/8 with broad equity selloff. ISRG has no direct Iran/EM exposure but indirect drag via global risk-off and elective-procedure deferrals is a watch item.